VRDN

30.68

1.41% -0.44

Dopo l'orario di chiusura: 30.50 -0.18 -0.59%

Viridian Therapeutics Inc (VRDN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$31.12

Aprire:

$30.8

Volume 24 ore:

1.06M

Relative Volume:

0.71

Capitalizzazione di mercato:

$2.93B

Reddito:

$305.00K

Utile/perdita netta:

$-328.98M

Rapporto P/E:

-7.1931

EPS:

-4.2652

Flusso di cassa netto:

$-309.60M

1 W Prestazione:

-3.76%

1M Prestazione:

+0.82%

6M Prestazione:

+101.44%

1 anno Prestazione:

+55.26%

Intervallo 1D:

$30.35

$31.54

Intervallo di 1 settimana:

$30.35

$31.89

Portata 52W:

$9.90

$34.04

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Nome

Viridian Therapeutics Inc

Settore

Healthcare (1131)

Industria

Biotechnology (631)

Telefono

617.272.4600

Indirizzo

221 CRESCENT STREET, WALTHAM

Dipendente

143

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

VRDN's Discussions on Twitter

Confronta VRDN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VRDN Viridian Therapeutics Inc	30.68	2.97B	305.00K	-328.98M	-309.60M	-4.2652
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-10	Reiterato	Wedbush	Outperform
2025-12-03	Iniziato	William Blair	Outperform
2025-11-24	Iniziato	Truist	Buy
2025-08-25	Ripresa	Jefferies	Buy
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-11-25	Iniziato	TD Cowen	Buy
2024-09-11	Reiterato	Needham	Buy
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-06-06	Iniziato	Goldman	Buy
2024-05-09	Downgrade	B. Riley Securities	Buy → Neutral
2024-05-09	Downgrade	Ladenburg Thalmann	Buy → Neutral
2023-06-14	Iniziato	BTIG Research	Buy
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-05-30	Iniziato	RBC Capital Mkts	Outperform
2023-04-17	Iniziato	Wells Fargo	Overweight
2023-03-30	Iniziato	Stifel	Buy
2022-12-19	Iniziato	Cowen	Outperform
2022-12-19	Iniziato	Needham	Buy
2022-12-16	Iniziato	Credit Suisse	Outperform
2022-12-01	Iniziato	H.C. Wainwright	Buy
2022-06-23	Iniziato	B. Riley Securities	Buy
2021-11-18	Iniziato	SVB Leerink	Outperform
2021-10-12	Iniziato	Evercore ISI	Outperform
2021-01-25	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie

Jan 03, 2026

Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily

Jan 03, 2026

Jan 02, 2026

Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat

Jan 02, 2026

Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus

Jan 02, 2026

Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan

Jan 02, 2026

What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in

Jan 02, 2026

Dec 31, 2025

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga

Dec 31, 2025

Viridian Therapeutics Earnings Notes - Trefis

Dec 31, 2025

Dec 30, 2025

Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 30, 2025

Dec 29, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 29, 2025

Dec 27, 2025

Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn

Dec 27, 2025

Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 27, 2025

Dec 24, 2025

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail

Dec 24, 2025

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail

Dec 24, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail

Dec 24, 2025

Dec 23, 2025

VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus

Dec 23, 2025

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat

Dec 23, 2025

Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks

Dec 23, 2025

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail

Dec 23, 2025

Dec 22, 2025

Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com

Dec 22, 2025

Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus

Dec 22, 2025

FDA grants priority review for Viridian’s thyroid eye disease drug - Investing.com

Dec 22, 2025

Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com

Dec 22, 2025

Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets

Dec 22, 2025

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire

Dec 22, 2025

Dec 20, 2025

Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда

Dec 20, 2025

Published on: 2025-12-20 23:42:03 - Улправда

Dec 20, 2025

Will Viridian Therapeutics Inc. stock deliver consistent dividendsGlobal Markets & Weekly High Return Stock Forecasts - ulpravda.ru

Dec 20, 2025

FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm

Dec 20, 2025

Dec 19, 2025

Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда

Dec 19, 2025

Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда

Dec 19, 2025

Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber

Dec 19, 2025

Published on: 2025-12-19 16:37:51 - Улправда

Dec 19, 2025

Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail

Dec 19, 2025

Dec 18, 2025

Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда

Dec 18, 2025

Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada

Dec 18, 2025

Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Trends & Smart Money Movement Alerts - Улправда

Dec 18, 2025

Dec 17, 2025

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail

Dec 17, 2025

Dec 16, 2025

Viridian Therapeutics stock reaches 52-week high at 33.67 USD By Investing.com - Investing.com Australia

Dec 16, 2025

Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com India

Dec 16, 2025

Dec 15, 2025